Skip to content

Polypharmacy Assessment In Cancer Patients

Evaluating the effect of the "OncoSTRIP" Polypharmacy Medication Assessment on Medication Use Satisfaction in the Elderly Patient with Cancer and Polypharmacy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21246
Enrollment
44
Registered
2020-01-27
Start date
2020-02-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly cancer patient with polypharmacy

Interventions

A standard polypharmacy assessment conducted by a pharmacist, following the OncoSTRIP method

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - > 65 years old - Use of 5 or more chronic, systemic drugs (anticancer drugs excluded) - Be able to read and understand the Dutch language - Having completed at least two cycles of anticancer treatment

Exclusion criteria

Exclusion criteria: There will be no specific exclusion criteria in this study.

Design outcomes

Primary

MeasureTime frame
The main objective of this study is to compare the patients' satisfaction with their medication before and after performing the polypharmacy assessment (i.e. at baseline vs at follow-up moment of one month after the polypharmacy treatment plan is discussed with the patient). This satisfaction wilt be measured with the 'Treatment Satisfaction Questionnaire for Medication' (TSQM)

Secondary

MeasureTime frame
Additionally, in order to assess if a possible difference in TSQM is clinically relevant, the minimal clinically important difference (MCID) wilt be determined, both through an anchor-based and distribution-based method. The `patients global impression of change' (PGIC) scale wilt be used as anchor. Other secondary objectives are measurements of the change in number of potential drug-related problems (DRPs) and the pill burden before and after the polypharmacy assessment. In addition, the number and type of pharmaceutical recommendations and implementation rate wilt be measured. Finally, a concise overview of the costs will be given.

Contacts

Public ContactElze Vrijkorte

Medisch Spectrum Twente

e.vrijkorte@mst.nl053- 4873110

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)